Articles On Cyclopharm (ASX:CYC)

Title Source Codes Date
Crucible: Dr Boreham’s A-To-Z of 2024 biotech

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

Stockhead CYC 6 days ago
Health Check: The robots are taking over biotech stock selection

Opyl has partnered to form the ‘world’s first’ AI-driven biotech fund Visioneering sees a brighter future – elsewhere – but its shares tumble  Cyclopharm breathes easy after decent lung transplant trial results   Who needs fund managers t...

Stockhead CYC 1 week ago
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Stockhead CYC 2 weeks ago
Health Check: Let there be light (therapy). Invion up 160pc on skin cancer trial news

Invion enrols its first patient in its Queensland skin cancer study Inoviq says it has the clinical proof to commercialise its early-stage ovarian cancer detection test Are we on the cusp of Trump-driven US healthcare M&A fiesta?   I...

Stockhead CYC 2 weeks ago
Cyclopharm doses first French patients with technegas in PRONOSPECT trial

Cyclopharm (ASX:CYC) has dosed its first French patients with its technegas lung imaging product in an ongoing trial. While the company received FDA approval in the U.S. last year, the company is conducting its ‘PRONOSPECT’ trial across 13...

themarketonline.com.au CYC 2 weeks ago
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Stockhead CYC 1 month ago
HEALTH CHECK: Lion City’s Orthocell approval provides a Singapore Sling-board to Asian markets

Orthocell wins Singaporean approval for its Remplir nerve-repair product Lumos wraps up $10 million whip-round amid surge of raisings in the sector ‘Nice tidy’ Cyclopharm eyes profitability from next year as US revenues grow   It’s not th...

Stockhead CYC 2 months ago
2 ASX healthcare shares rocketing over 16% on Big US news

There have been some big moves in the healthcare sector on Thursday. For example, the two ASX healthcare shares listed below are up at least 16% in morning trade thanks to big news in the United States. Here's what you need to know about th...

Motley Fool CYC 2 months ago
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Stockhead CYC 2 months ago
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Stockhead CYC 3 months ago
Alive and Kicking: Noxopharm has difficult brain cancer in its sights

Noxopharm says two novel drug candidates significantly reduced glioblastoma (brain cancer) cell growth in preclinical models. Percheron Therapeutics announces “very encouraging” new data for its epilepsy program Cyclopharm is off to a soli...

Stockhead CYC 3 months ago
FNArena Corporate Results Monitor – 28-08-2024

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck Welcome to the FNArena Corporate Results Monitor. Today's Reports:...

FNArena CYC 3 months ago
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

Stockhead CYC 4 months ago
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Stockhead CYC 4 months ago
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Stockhead CYC 5 months ago
Bell Potter names the best ASX healthcare stocks to buy in FY25

Looking for exposure to the healthcare sector in FY 2025? If you are, then check out the three ASX shares listed below. They have just been tipped as Bell Potter's top healthcare stocks to buy now: Aroa Biosurgery Ltd (ASX: ARX) Aroa Biosu...

Motley Fool CYC 5 months ago
Cyclopharm's Technegas receives pass-through status from US agency

Cyclopharm (ASX:CYC) has announced that Technegas received Pass-Through status from the US Centre for Medicare and Medicade Services.

BiotechDispatch CYC 6 months ago
Daily ASX Market Close: Market ahead on low GDP lift | June 5, 2024

The ASX200 closed up 0.4% – thanks to a very small rise in Australia’s latest Gross Domestic Product data. Quarterly GDP rose just 0.1%, which is the slowest pace of GDP growth in one-and-a-half-years.  As far as the sectors went toda...

themarketonline.com.au CYC 6 months ago
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Stockhead CYC 6 months ago
Market Close: ASX edges up with mostly smiles on green dials

The ASX200 closed the day up 0.8%. All sectors bar one finished in the green. Real-estate lead the way, up 1.8%, tele-communications and staples followed, both gaining around 1.3%. The energy sector was the only sector to fall short,...

themarketonline.com.au CYC 6 months ago
Closing Bell: Tech, Retail, and Banking stocks feel the heat as ASX tumbles over 1pc

ASX drops over 1pc as tech, retail, banks fall; energy resists Bond yields surge, impacting goldies Ethereum ETFs approved, await filings   Energy was the only sector showing some sort of resistance on Friday as the ASX was engulfed in a...

Stockhead CYC 6 months ago
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead CYC 7 months ago
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Stockhead CYC 7 months ago
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Stockhead CYC 7 months ago
Dr Boreham’s Crucible: Universal Biosensors chief John Sharman is exasperated about investor indifference

When your columnist caught up with Universal Biosensors chief John Sharman early last Tuesday, he was exasperated about investor indifference towards the company. Indeed. In the spirit of Easter, one could say the stock indeed had been cruc...

Stockhead CYC 8 months ago
Dr Boreham’s Crucible

DR BOREHAM’S CRUCIBLE: UNIVERSAL BIOSENSORS By TIM BOREHAM When your columnist caught up with Universal Biosensors chief John Sharman early last Tuesday, he was exasperated about investor indifference towards the company. Indeed. In the spi...

Stockhead CYC 8 months ago
Stocks of the Hour: Cyclopharm, lonic Rare Earths, Metals Acquisition

19 Mar 2024 - A snapshot of the stocks on the move, featuring Cyclopharm (ASX:CYC), lonic Rare Earths (ASX:IXR) and Metals Acquisition (ASX:MAC).

FNN CYC 9 months ago
Stocks of the Hour: Cyclopharm, lonic Rare Earths, Metals Acquisition

  Cyclopharm (ASX:CYC) announced that its first USA Technegas clinical patients were imaged last week at two preeminent clinical sites located in St Louis, Missouri and Stanford, California. These landmark events follow US FDA approval of T...

ShareCafe CYC 9 months ago
Cyclopharm says milestone achieved with first US patients imaged with Technegas

The company said these events follow the US FDA approval of Technegas last October and the subsequent rollout of its plan for market penetration in medical facilities across the US.

BiotechDispatch CYC 9 months ago
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Stockhead CYC 9 months ago
FNArena Corporate Results Monitor – 29-02-2024

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((4DX)) - 4DMedical ((APM)) - APM Human Services International ((AMI)) - Aurelia Metals ((ACL)) - Australian Clinical Labs ((AVG)) - Australian Vintage ((AVD)) - Avada Gro...

FNArena CYC 9 months ago
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead CYC 9 months ago
Cyclopharm announces the appointment of new chief financial officer

Radiopharmaceutical company Cyclopharm (ASX:CYC) has announced the appointment of Jason Smith as its chief financial officer.

BiotechDispatch CYC 10 months ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead CYC 1 year ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead CYC 1 year ago
Why Fletcher Building, Navigator Global, Siteminder, and Skycity shares are dropping today

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a small decline. At the time of writing, the benchmark index is down 0.3% to 7,028.8 points. Four ASX shares that are falling more than most toda...

Motley Fool CYC 1 year ago
Can you guess which ASX 200 share is crashing 10% on Monday?

The Fletcher Building Ltd (ASX: FBU) share price has returned from its suspension and crashed deep into the red. In morning trade, the ASX 200 building materials company's shares are down 10% to $4.02. Why is this ASX 200 share crashing? I...

Motley Fool CYC 1 year ago
Dr Boreham’s Crucible: Dimerix has so far proved the doubters wrong. Next stop – the US

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

Stockhead CYC 1 year ago
Experts say these ASX dividend stocks are top buys

The good news for income investors is that there are a lot of dividend stocks to choose from on the ASX. If you're paralysed by choice, don't worry! That's because listed below are a couple of ASX dividend shares that are highly recommende...

Motley Fool CYC 1 year ago
Dr Boreham’s Crucible: Cyclopharm

FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports. By Tim Boreham ASX code: ((CYC)) Share price: $2.57 Market cap: $270.4 million Shares on issue: 93,896,326 Chief executive officer: James McBrayer Board: D...

FNArena CYC 1 year ago
ScoPo’s Powerplays: ASX health stocks fall but Dimerix up 150% on drug licensing deal

ASX health sector falls in line with broader markets as macroeconomic factors continue to create volatility Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease US FDA approves Cyclofarm’s lung imag...

Stockhead CYC 1 year ago
Top brokers name 3 ASX shares to buy today

Many of Australia's top brokers have been busy adjusting their financial models again, leading to the release of a number of broker notes this week. Three ASX shares brokers have named as buys this week are listed below. Here's why they ar...

Motley Fool CYC 1 year ago
The record CSL dividend is being paid today. Here's the lowdown

Today is a good day to be a CSL Limited (ASX: CSL) shareholder. That's because later today the biotherapeutics company will be rewarding them with its biggest ever dividend. Payday for the CSL dividend In August, CSL released its FY 2023 r...

Motley Fool CYC 1 year ago
Analysts expect big juicy yields from these ASX dividend shares

If you want to boost your income portfolio this week, then it could be worth checking out the high-yield ASX dividend stocks listed below. Here's what analysts are saying about them: Charter Hall Group (ASX: CHC) The first ASX dividend sh...

Motley Fool CYC 1 year ago
Here are the top 10 ASX 200 shares today

The S&P/ASX 200 Index (ASX: XJO) has just endured a horror day as investors scramble for the exits amid widespread fears over ASX sales. By the end of today's trading, the ASX 200 ha...

Motley Fool CYC 1 year ago
Leading brokers name 3 ASX shares to buy today

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...

Motley Fool CYC 1 year ago
Why CSL, Cyclopharm, Dicker Data, and Fletcher Building shares are pushing higher

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a sizeable decline. At the time of writing, the benchmark index is down 1.3% to 6,942.9 points. Four ASX shares that are not letting that holding them back ar...

Motley Fool CYC 1 year ago
Cyclopharm announces US approval for nuclear medicine imaging agent

The US FDA has approved Cyclopharm's (ASX:CYC) Technegas for the diagnosis and management of Pulmonary Embolism.

BiotechDispatch CYC 1 year ago
TMH Market Close: ASX200 drops a little in lead up to RBA’s Tuesday interest rates call

The ASX200 shed 0.2 of a per cent today as the market awaits the Reserve Bank’s interest rates decision tomorrow. Utilities was the best-performing sector today – up .6 of a per cent, while healthcare dropped 1.3 per cent. In the gree...

themarketherald.com.au CYC 1 year ago
In Case You Missed It: A maiden resource and high tech propeller deal

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Stockhead CYC 1 year ago